Valuation Pelthos Therapeutics Inc.

Stocks

Market Closed - NYSE 16:00:00 2026-08-28 EDT			5-day change	1st Jan Change
24.73 ^USD	-1.08%		-3.06%	-20.23%

08-14	Oppenheimer Adjusts Pelthos Therapeutics PT to $64 From $66, Maintains Outperform Rating	MT
08-13	Pelthos Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	3.864	95.69	94.68	-	-
Change	-	2,376.4%	-1.05%	-	-
Enterprise Value (EV)	3.864	95.69	94.68	94.68	94.68
Change	-	2,376.4%	-1.05%	0%	0%
P/E	-0.45x	-1.35x	-1.44x	-8.79x	10.7x
PBR	-	-	-	-	-
PEG	0x	-0x	0.1x	0.1x	-0x
Capitalization / Revenue	-	5.7x	1.49x	0.84x	0.59x
EV / Revenue	-	0x	1.49x	0.84x	0.59x
EV / EBITDA	-	-0x	-2.98x	14.1x	4.01x
EV / EBIT	-	-0x	-1.97x	-10.8x	4.22x
EV / FCF	-	-	-8.61x	94.7x	2.1x
FCF Yield	-	-	-11.6%	1.06%	47.5%
Dividend per Share ²	-	-	-	-	-
Rate of return	-	-	-	-	-
EPS ²	-14.3	-23.04	-17.12	-2.813	2.302
Distribution rate	-	-	-	-	-
Net sales ¹	-	16.8	63.75	112.2	159.2
EBITDA ¹	-	-24.68	-31.75	6.7	23.6
EBIT ¹	-	-32.43	-47.97	-8.737	22.46
Net income ¹	-7.955	-43.32	-62.08	-24.96	10.79
Net Debt	-	-	-	-	-
Reference price ²	6.41	31.00	24.73	24.73	24.73
Nbr of stocks (in thousands)	603	3,087	3,828	-	-
Announcement Date	3/27/25	3/19/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
PELTHOS THERAPEUTICS INC.	-1.44x	-	-	-	94.68M
ELI LILLY AND COMPANY	33.44x	12.14x	24.6x	0.59%	1,047B
JOHNSON & JOHNSON	29.82x	-	-	2%	646B
ABBVIE INC.	32.61x	7.57x	15.74x	2.68%	451B
ROCHE HOLDING AG	19.99x	4.75x	11.76x	2.79%	355B
NOVARTIS AG	21.76x	5.62x	13.93x	2.85%	291B
ASTRAZENECA PLC	20.88x	4.29x	12.24x	2.06%	252B
AMGEN INC.	27.35x	7.07x	12.56x	2.33%	234B
NOVO NORDISK A/S	13.25x	4.77x	9.95x	3.83%	203B
GILEAD SCIENCES, INC.	-44.51x	6.43x	25.11x	2.26%	181B
Average	15.31x	6.58x	15.74x	2.38%	365.94B
Weighted average by Cap.	24.24x	8.07x	17.81x	1.97%